Scaling up and industrialization the production and purification of viral vectors for therapeutic use: Challenges and progress
January 27-31, 2019
With several recent FDA approvals and a strong drug pipeline, gene therapy is coming of age. With this comes the requirement to ensure that there are robust manufacturing processes in place in order to scale with demand and to make these therapies readily accessible to those who need them. However, current manufacturing processes for gene therapies have often been developed with limited scalability in mind and large shifts in technology have to take place to enable industrialization. This also has to be done while keeping costs in mind. Here, we will present a case study which illustrates the challenges and solutions to scale both up and downstream process steps required to manufacture adenovirus. After implementation of a bioreactor, the bioreactor scale increased 125 fold, from 0.53m2 to 66 m2. With the implementation of several scalable unit operations on the downstream, this took 1 day as opposed to 3 – 4 days required for the entire optimized process generating purified viral vector for the successfully completion of a global in vivo toxicology study. Altogether, the practicalities around manufacturing virus to industrial scale.
Please click Additional Files below to see the full abstract.
Rachel Legmann, Brian Gardell, Deepika Vallabhaneni, Heather Mallory, Keen Chung, Irit Meivar-Levy, and Sarah Ferber, "Scaling up and industrialization the production and purification of viral vectors for therapeutic use: Challenges and progress" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). https://dc.engconfintl.org/cell_gene_therapies_vi/17